TY - JOUR
T1 - Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure
AU - Gajewski, James L.
AU - Ho, Winston G.
AU - Feig, Stephen A.
AU - Hunt, Lynne
AU - Kaufman, Nancy
AU - Champlin, Richard E.
PY - 1990/8
Y1 - 1990/8
N2 - Thirty-four patients received bone marrow transplants from unrelated donors. Donors and recipients were phenotypically matched for 6 of 6 HLA-A, B, and DR antigens in 27 cases and at 5 of 6 antigens in 7 cases. Twenty-three patients had leukemia, six had myelodysplasia, and five had aplastic anemia. Twenty-four patients had durable engraftment. Five died of sepsis prior to engraftment. Five patients failed to engraft; 2 of these patients had autologous bone marrow recovery. Seventeen patients developed grade >II acute graft-versus-host disease for an actuarial probability of 67±20%. The severity of acute graft-versus-host disease and its mortality appeared increased for recipients matched for 5 of 6 HLA-A, B, and DR antigens. Of the 34 patients, 13 (38%) are alive; actuarial survival beyond 6 months is 44±17%. None of the 25 leukemia and myelodysplasia patients achieving engraftment have relapsed. For leukemia and myelodysplasia recipients of 6 of 6 HLA-matched grafts, actuarial survival at 6 months was 55±21% compared with 14±26% for recipients matched for 5 of 6 HLA loci (P=0.19). Infection and acute graft-versus-host disease were the primary causes of death in the engrafted patients. Survival for aplastic anemia patients was 20%. Late deaths due to pneumonia and bronchiolitis obliterans occurred after one year in 2 patients. Closely matched unrelated donor bone marrow transplants are associated with a higher incidence of graft failure and graft-versus-host disease than typically reported for transplants from HLA-identical siblings, but these preliminary data suggest a lower rate of relapse.
AB - Thirty-four patients received bone marrow transplants from unrelated donors. Donors and recipients were phenotypically matched for 6 of 6 HLA-A, B, and DR antigens in 27 cases and at 5 of 6 antigens in 7 cases. Twenty-three patients had leukemia, six had myelodysplasia, and five had aplastic anemia. Twenty-four patients had durable engraftment. Five died of sepsis prior to engraftment. Five patients failed to engraft; 2 of these patients had autologous bone marrow recovery. Seventeen patients developed grade >II acute graft-versus-host disease for an actuarial probability of 67±20%. The severity of acute graft-versus-host disease and its mortality appeared increased for recipients matched for 5 of 6 HLA-A, B, and DR antigens. Of the 34 patients, 13 (38%) are alive; actuarial survival beyond 6 months is 44±17%. None of the 25 leukemia and myelodysplasia patients achieving engraftment have relapsed. For leukemia and myelodysplasia recipients of 6 of 6 HLA-matched grafts, actuarial survival at 6 months was 55±21% compared with 14±26% for recipients matched for 5 of 6 HLA loci (P=0.19). Infection and acute graft-versus-host disease were the primary causes of death in the engrafted patients. Survival for aplastic anemia patients was 20%. Late deaths due to pneumonia and bronchiolitis obliterans occurred after one year in 2 patients. Closely matched unrelated donor bone marrow transplants are associated with a higher incidence of graft failure and graft-versus-host disease than typically reported for transplants from HLA-identical siblings, but these preliminary data suggest a lower rate of relapse.
UR - http://www.scopus.com/inward/record.url?scp=0025150433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025150433&partnerID=8YFLogxK
U2 - 10.1097/00007890-199008000-00015
DO - 10.1097/00007890-199008000-00015
M3 - Article
C2 - 2143325
AN - SCOPUS:0025150433
SN - 0041-1337
VL - 50
SP - 244
EP - 249
JO - Transplantation
JF - Transplantation
IS - 2
ER -